Clinical-biological characteristics of DLBCL patients at diagnosis (n = 250)
| Variable . | n (%) of patients . |
|---|---|
| Age, y | |
| Median (range) | 56 (13-87) |
| ≤60 | 152 (62) |
| >60 | 93 (38) |
| Median (range) follow-up, mo | 89 (18-273) |
| Sex | |
| Male | 129 (52) |
| Female | 120 (48) |
| Performance status ECOG ≥ 2 | 76 (34) |
| β2 microglobulin > 3 mg/L | 76 (42) |
| Albumin < 3.5 g/dL | 73 (39) |
| Elevated LDH | 130 (59) |
| Elevated C-reactive protein | 79 (59) |
| IPI | |
| 0-1 | 53 (24) |
| 2 | 55 (25) |
| 3 | 75 (34) |
| 4-5 | 39 (17) |
| Age-adjusted IPI | |
| 0-1 | 84 (38) |
| 2-3 | 137 (62) |
| Immunostaining | |
| GCB | 52 (45) |
| Non-GCB | 64 (55) |
| Treatment (n = 224) | |
| Rituximab based | 153 (68) |
| R-CHOP/R-COMP | 85 (37.5) |
| R-MegaCHOP | 67 (30) |
| Others with R | 1 (0.5) |
| Without rituximab | 71 (32) |
| CHOP | 18 (8) |
| MegaCHOP | 46 (21) |
| Others | 7 (3) |
| Variable . | n (%) of patients . |
|---|---|
| Age, y | |
| Median (range) | 56 (13-87) |
| ≤60 | 152 (62) |
| >60 | 93 (38) |
| Median (range) follow-up, mo | 89 (18-273) |
| Sex | |
| Male | 129 (52) |
| Female | 120 (48) |
| Performance status ECOG ≥ 2 | 76 (34) |
| β2 microglobulin > 3 mg/L | 76 (42) |
| Albumin < 3.5 g/dL | 73 (39) |
| Elevated LDH | 130 (59) |
| Elevated C-reactive protein | 79 (59) |
| IPI | |
| 0-1 | 53 (24) |
| 2 | 55 (25) |
| 3 | 75 (34) |
| 4-5 | 39 (17) |
| Age-adjusted IPI | |
| 0-1 | 84 (38) |
| 2-3 | 137 (62) |
| Immunostaining | |
| GCB | 52 (45) |
| Non-GCB | 64 (55) |
| Treatment (n = 224) | |
| Rituximab based | 153 (68) |
| R-CHOP/R-COMP | 85 (37.5) |
| R-MegaCHOP | 67 (30) |
| Others with R | 1 (0.5) |
| Without rituximab | 71 (32) |
| CHOP | 18 (8) |
| MegaCHOP | 46 (21) |
| Others | 7 (3) |
COMP, cyclophosphamide, vincristine, nonpegylated liposomal doxorubicin, and prednisolone; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell–like; LDH, lactate dehydrogenase.